Delving into the Latest Updates on Pranoprofen with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Difen Oculum, Niflan, Oftalar

+ [9]

Target

COX

Mechanism

COX inhibitors(Cyclooxygenases inhibitors)

Therapeutic Areas

Nervous System DiseasesEye DiseasesOther Diseases

Active Indication

Ocular inflammationFeverPain

Inactive Indication-

Originator Organization-

Active Organization

Senju Pharmaceutical Co., Ltd.AbbVie AS

JW SHINYAK Corp.

+ [1]

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

JP (04 Jun 1981)

Regulation-

Login to view timeline

Structure

Molecular FormulaC15H13NO3

InChIKeyTVQZAMVBTVNYLA-UHFFFAOYSA-N

CAS Registry52549-17-4

As is reported, NSAIDs(pranoprofen ,bromfenac) eye drops can suppress herpes simplex virus（HSV-1） reactivation and reduce inflammatory reaction in vitro and in vivo. In Clinical, there is no risk of corneal tissue melting, glaucoma, cataract by topical application of NSAIDs. To explore more effective clinical treatment of viral keratitis patients to control the inflammatory damage, save the visual function and reduce the recurrence of the virus ,we observe the effect of anti-inflammatory and inhibition of recurrence on the herpes simplex virus after topical NSAIDs administration.

Start Date01 Nov 2016

Sponsor / Collaborator

Peking Union Medical College

NCT03712670 / CompletedNot ApplicableIIT

Treatment of Exudative Age-Related Macular Degeneration With Aflibercept Combined With Pranoprofen Eye Drops or Nutraceutical Support With Omega-3: A Randomized Trial

Although evidence have clearly proved that intravitreal injection of vascular endothelial growth factor antagonists prevents vision loss and may even improve visual acuity in patients with neovascular AMD, a significant percentage of patients continue to lose visual acuity. Moreover, monthly intravitreal injections represent a burden for society as well as the caregiver.
Combination therapy with either topical 0.1% pranoprofen or nutraceutical support with AREDS2 formula plus omega-3 might act synergistically with intravitreal injection, offering valuable therapeutic support to aflibercept injections in patients requiring long-term treatment.

Start Date01 Jan 2016

Sponsor / Collaborator

Università degli Studi di Brescia

100 Clinical Results associated with Pranoprofen

Login to view more data

100 Translational Medicine associated with Pranoprofen

Login to view more data

100 Patents (Medical) associated with Pranoprofen

Login to view more data

138

Literatures (Medical) associated with Pranoprofen

01 Oct 2024·Investigative Ophthalmology & Visual Science

Mesenchymal Stem Cells-Derived Exosomal miR-223-3p Alleviates Ocular Surface Damage and Inflammation by Downregulating Fbxw7 in Dry Eye Models

Article

Author: Zeng, Li ; Wang, Guifang ; Liu, Yuzhen ; Zhu, Yujie ; Yang, Mulin

PurposeOur previous study indicated that exosomes derived from mouse adipose-derived mesenchymal stem cells (mADSC-Exos) alleviated the benzalkonium chloride (BAC)-induced mouse dry eye model. However, the specific active molecules in mADSC-Exos that contribute to anti-dry eye therapy remain unidentified. In this study, we aimed to investigate the efficacy and mechanisms of miR-223-3p derived from mADSC-Exos in dry eye models.MethodsEnzyme-linked immunosorbent assay (ELISA) experiments were conducted to determine miR-223-3p derived from mADSC-Exos that exerted anti-inflammatory effects on hyperosmolarity-induced mouse corneal epithelial cells (MCECs). The therapeutic efficacy of miR-223-3p was evaluated in mice with dry eye induced by either BAC or scopolamine (Scop). Mice were randomly assigned to 5 groups: sham, model, miR-223-3p overexpression, miR-223-3p knockdown, and 0.1% pranoprofen (positive group). Post-treatment, the severity of dry eye symptoms, and the pro-inflammatory cytokine levels were assessed. The effect of miR-223-3p on silencing the target gene was verified using ELISA and dual luciferase reporter assays.ResultsThe mADSC-Exos that knocked out miR-223-3p did not reduce interleukin (IL)-6 content. Supplementing with miR-223-3p could restore the reduction of IL-6. The miR-223-3p effectively ameliorated ocular surface damage and decreased pro-inflammatory cytokines or chemokines in both BAC- and Scop-induced mouse dry eye models. Furthermore, miR-223-3p inhibited cell apoptosis. F-box and WD repeat domain-containing 7 (Fbxw7) was the potential direct target of miR-223-3p. The miR-223-3p suppressed the 3'-untranslated region of Fbxw7. The Fbxw7 knockdown suppressed hyperosmolarity-induced inflammation in MCECs.ConclusionsThe mADSC-derived exosomal miR-223-3p mitigates ocular surface damage and inflammation, indicating its potential as a promising treatment option for dry eye.

01 Sep 2024·Panminerva MedicaQ4 · MEDICINE

Pranoprofen inhibits endoplasmic reticulum stress-mediated apoptosis of chondrocytes

Q4 · MEDICINE

Article

Author: Mu, Yanping ; Gong, Yuqing ; Yan, Peipei ; Zhang, Wanqiang

BACKGROUNDEndoplasmic reticulum stress (ERS) is a newly discovered pathway that causes apoptosis. At present, there is little research about the non-steroidal anti-inflammatory drug (NSAID) on the apoptosis of chondrocytes CHs. Our study aimed to test the anti-apoptosis effects of pranoprofen (PF), a specific prostaglandin E2 (PGE2) inhibitor, on human CHs.METHODSWe firstly made a distinguish about the levels of PGE2, ERS, and apoptosis between cartilage with and without OA. Then CHs isolated from healthy cartilage were pretreated H2O2 or tunicamycin (TM) to activate ERS, and then exposed to PF. Expression of type II collagen, Runx-2, COX-9, SOD1, GPX1, GRP78, CHOP, caspase-12, ROS level, and apoptosis cell ratio was determined by immunofluorescence, Western blot, RT-PCR, or flow cytometry respectively.RESULTSWe found that oxidative stress, PGE2, ERS, and apoptosis were upregulated in OA cartilage. In addition, H2O2 and TM could increase the levels of PGE2, GRP78, CHOP, caspase-12, and reactive oxygen species (ROS), resulting in the degeneration of CHs. PF significantly reduced the expression of PGE2 and suppressed the ERS and apoptosis caused by H2O2 and TM, showing a protective function of CHs degeneration.CONCLUSIONSThis study demonstrates the anti-apoptotic effect of PF in the abrogation of the ERS-mediated apoptosis in human CHs, suggesting a new mechanism of PF in the treatment of OA.

01 May 2024·Acta Ophthalmologica

Topical non‐steroidal anti‐inflammatory drugs for central serous chorioretinopathy: A systematic review and meta‐analysis

Review

Author: Grauslund, Jakob ; Klefter, Oliver N ; Boberg-Ans, Lars C ; Schneider, Miklos ; Hajari, Javad N ; Subhi, Yousif ; Vangsted, Andreas ; van Dijk, Elon H C ; Larsson, Janni M E

AbstractCentral serous chorioretinopathy (CSC) is a prevalent exudative maculopathy and the ongoing verteporfin shortage restricts current treatment possibilities. Topical non‐steroidal anti‐inflammatory drugs (NSAID) have previously been proposed as a treatment for CSC, although its exact efficacy remains unclear. In this systematic review and meta‐analysis, we outlined the efficacy of topical NSAIDs for the treatment of CSC. We searched 11 literature databases on 13 December 2022, for any study describing topical NSAID treatment for CSC. Thirteen eligible studies were included with a total of 1001 eyes of 994 patients with CSC. Six studies were case reports, two were cohort studies and five were non‐randomized comparative studies. Where specified, topical NSAIDs used were bromfenac 0.09%, diclofenac 0.1%, ketorolac 0.4% and 0.5%, pranoprofen 0.1%, and nepafenac 0.1% and 0.3%. Studies were predominantly of cases with acute CSC and several case studies reported treatment outcomes simultaneously with discontinuation of corticosteroid use, which complicated treatment evaluation. Meta‐analyses of comparative studies revealed a statistically significant but clinically irrelevant best‐corrected visual acuity improvement of −0.04 logMAR (95% CI: −0.07 to −0.01 logMAR; p = 0.01) at 1‐month follow‐up, which became statistically insignificant at 3‐month follow‐up (−0.03 logMAR; 95% CI: −0.06 to 0.003 logMAR; p = 0.08). Further, we found no benefit in complete subretinal fluid resolution at 1‐month follow‐up (OR: 1.20; 95% CI: 0.81–1.76; p = 0.37) or 3‐month follow‐up (OR: 1.17; 95% CI: 0.86 to 1.59; p = 0.33). Taken together, available evidence does not support the use of topical NSAIDs for the treatment of CSC.

100 Deals associated with Pranoprofen

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01578	Pranoprofen	S01BC09	DB13514

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Ocular inflammation	KR	JW SHINYAK Corp.	25 Sep 1998
Fever	JP	-	22 Nov 1988
Pain	JP	-	20 Oct 1988

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ARVO2004	Not Applicable	-	40	Pranoprofen 0.1%	(bvfuiarowf) = corneal confocal microscopy documented thinner epithelium in group 2 vs group 1 bzfuxdkybn (nqgymrertn ) View more	-	01 May 2004
				Diclofenac 0.1%